Loading
Glycyx Therapeutics
Glycyx Therapeutics is testing whether axelopran, a pill that blocks opioid effects outside the brain, can help immunotherapy work in people who take opioids for cancer pain, without taking away their pain relief.
Also called: Glycyx MOR, Inc.Glycyx
Overview
Glycyx Therapeutics develops axelopran, a peripherally acting mu-opioid receptor antagonist first developed for opioid-induced constipation, as an addition to PD-1 and PD-L1 checkpoint inhibitors in patients taking opioid analgesics. The company states axelopran has been given to 544 patients in earlier trials. Its first cancer trial, NCT07662720 (MORALE-HN01), a phase 1/2 study of axelopran with pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma, is registered with Glycyx as sponsor and NCI, Emory University and the University of Pittsburgh as collaborators. In fiscal year 2026 NCI awarded Glycyx MOR, Inc. USD 1,047,803 under SBIR award 5R44CA306565-02 for that trial.
Headquarters
San Francisco, CA, US
Scorecard
All companies#627of 1706 companies, score 5
- phase 1/2 +1
- targets +2
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 5R44CA306565-02: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1 CPS >1) | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1Phase 2Oral peripherally acting mu-opioid receptor antagonist
Axelopran is a pill that blocks opioid effects outside the brain. Glycyx Therapeutics is testing it with immunotherapy in head and neck cancer in people who take opioids for pain.
Notes
- The award is made to Glycyx MOR, Inc.; the trial registry and website use Glycyx Therapeutics. Read on glycyx.com, ClinicalTrials.gov and NIH RePORTER on 4 November 2026.
Connected
5cancers
fronts
targets
drugs
Phase 2Oral peripherally acting mu-opioid receptor antagonist
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
glycyx.com · 2
ClinicalTrials.gov · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/